Špela Gubič

Špela Gubič
no.: 53671 source: ARIS

researcher – not employed in research organisation
  spela.gubicat signffa.uni-lj.si
Edit
Research activity

Code Science Field Subfield
1.09.00  Natural sciences and mathematics  Pharmacy   
Bibliography Representative bibliographic units | Personal | COBISS+
source: COBISS
source: SICRIS
Evaluation (metodology)
Evaluation of bibliographic research performance indicators according to ARIS methodology
source: COBISS
source: ARIS
Points
64.38
A''
16.94
A'
46.18
A1/2
54.73
CI10
47
CImax
34
h10
3
A1
0.25
A3
0
Data for the last 5 years (citations for the last 10 years) on November 11, 2025; Data for score A3 calculation refer to period 2020-2024
Data for ARIS tenders ( 21.05.2024 – Target research programmes, archive )
Citations Citations for bibliographic records in COBIB.SI that are linked to records in citation databases
source: WoS source: Scopus source: COBISS
Database Linked records Citations Pure citations Average pure citations
WoS 4  51  46  11.5 
Scopus 4  51  46  11.5 
Education
source: ARIS
Level of education Professional title Study subject Faculty Year
2nd cycle master's degree  B. Sc.     SI University of Ljubljana, Faculty of Pharmacy 2019 
Doctoral dissertations and other final papers Show
Obtaining results now
source: COBISS
Research projects Legend
source: ARIS
no. Code Title Period Head
1. J7-4635  MitoCan - Preclinical development of new Mitochondrial ion channel inhibitors for Cancer therapy   10/1/2022 - 9/30/2026  PhD Lucija Peterlin Mašič   6,792 
2. J1-3030  MTAvsAMR: new MultiTargeting Antibiotics against AntiMicrobial Resistance   10/1/2021 - 9/30/2025  PhD Lucija Peterlin Mašič   1,098 
3. L3-3177  Safety evaluation of cannabidiols and implications for public health and consumers behaviour   10/1/2021 - 12/31/2024  PhD Alja Štern   5,211 
4. N1-0098  Discovery and mechanism of action of novel hEag1 potassium channel lead molecules with anti-cancer activity   1/1/2019 - 12/31/2022  PhD Lucija Peterlin Mašič   1,000 
5. J1-9192  New anticancer leads for emerging cancer target potassium ion channels hEag1 and its validation in lymphoma tumors   7/1/2018 - 6/30/2021  PhD Lucija Peterlin Mašič   2,481 
6. J1-8152  Inhibicija prenove celične stene Staphylococus aureus (Slovene)   5/1/2017 - 4/30/2020  PhD Dušan Turk   2,202 
Confirmation required
Views history
Favourite